NCT06689839 · EnCompass Technologies, Inc.
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
(SHIELD)
What this study is about
The objective of this study is to compare the safety and effectiveness of the F2 Cerebral Protection System (CPS) to a the usual treatment control group in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR)
View original scientific description
The objective of this study is to compare the safety and effectiveness of the F2 Cerebral Protection System (CPS) to a standard of care control group in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR)
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Age ≥ 50 years.
- Patient meets the established criteria and indications for commercially available TAVR via transfemoral access and is scheduled to undergo TAVR per their treating physician.
- Patient is willing and able to comply with protocol-specified follow-up evaluations.
- Patient is able and willing to provide written informed consent.
- Patient meets all criteria for use of control device (Sentinel device, per IFU). Key
Exclusion criteria
- General Exclusion Criteria:
- Patient requires an urgent or emergent TAVR procedure.
- Any interventional cardiovascular procedure performed within 30 days prior to TAVR procedure or planned within 30 days post-TAVR procedure.
- Diagnostic cardiac catheterization within 10 days prior to TAVR procedure.
- Evidence of an acute myocardial infarction within 3 months prior to TAVR procedure.
- Prior prosthetic heart valve in any position.
- Known intracardiac thrombus.
- Active infection or endocarditis.
- Patient is contraindicated for anti-platelet and/or anticoagulant therapy.
- Patient refuses blood transfusion.
- Renal insufficiency (creatinine \> 2.5 mg/dL or GFR \< 30) and/or renal replacement therapy at the time of screening.
- Patients with hepatic failure (Child-Pugh class C).
- Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) \< 30%.
- Females who are pregnant or nursing or plan to become pregnant during their participation in the study. Neurological Exclusion Criteria:
- Modified Rankin Scale (mRS) ≥ 2 at screening.
- Cerebrovascular event including TIA within 6 months of the procedure.
- Patient has active major psychiatric disease, known mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol or confound the data interpretation.
- Patient has severe visual, auditory, or learning impairment.
- Patient has neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities. Magnetic Resonance Imaging Exclusion Criteria:
- Contraindications to MRI (participants with MR unsafe implants including implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure).
- High risk of complete AV block after TAVR, with the need of permanent pacemaker.
- Claustrophobia precluding MRI scanning. Anatomical and CT Exclusion Criteria:
- Severe peripheral arterial, abdominal aortic, or thoracic aortic disease that precludes delivery sheath, vascular access or filter deployment.
- Presence of cardiovascular implant in aorta and/or peripheral access vessels.
- Access vessels with excessive tortuosity.
- Aortic arch, which is heavily calcified, severely atheromatous, or severely tortuous.
Where
- Naples, Florida
- Indianappolis, Indiana
- Detroit, Michigan
- Kansas City, Missouri
- New York, New York
- Cleveland, Ohio
- Columbus, Ohio
- Charlottesville, Virginia
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Nov 20, 2025 · Source of record for eligibility and locations